Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Abstract

Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.

• Authors: Gautam Borthakur, Jorge E Cortes, Elihu E Estey, Elias Jabbour, Stefan Faderl, Susan O'Brien, Guillermo Garcia-Manero, Tapan Mahendra Kadia, Xuemei Wang, Keyur Patel, Rajyalakshmi Luthra, Charles Koller, Mark Brandt, Farhad Ravandi, Hagop Kantarjian
• Journal: American journal of hematology (Am J Hematol) Vol. 89 Issue 10 Pg. 964-8 (Oct 2014) ISSN: 1096-8652 [Electronic] United States
• PMID: 24990142 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 Wiley Periodicals, Inc.

Chemical References

• Aminoglycosides
• Antibodies, Monoclonal, Humanized
• Core Binding Factors
• Cytarabine
• Granulocyte-Macrophage Colony-Stimulating Factor
• Gemtuzumab
• Vidarabine
• fludarabine

Topics

• Adult
• Aged
• Aminoglycosides (administration & dosage, adverse effects)
• Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Core Binding Factors
• Cytarabine (administration & dosage, adverse effects)
• Disease-Free Survival
• Female
• Gemtuzumab
• Granulocyte-Macrophage Colony-Stimulating Factor (administration & dosage, adverse effects)
• Humans
• Leukemia, Myeloid, Acute (drug therapy, genetics, mortality)
• Male
• Middle Aged
• Survival Rate
• Vidarabine (administration & dosage, adverse effects, analogs & derivatives)